Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q2 2019 · 10-Q
Revenue$666.00K$666.00K+10.3% vs Q2 2018 Net Income$3.70M$3.70MN/M vs Q2 2018 EPS Diluted$0.21$0.21+5.0% vs Q2 2018 Operating Income-$3,568,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$1,884,000— Margins · derivedOperating margin-535.7%−20.7 pt vs Q2 2018
Net margin555.7%+1038.5 pt vs Q2 2018
ended Feb 28, 2019 · filed Apr 10, 2019 · 41 d after period end